Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
Phase I/II open-label randomized multicenter trial to assess immunogenicity and safety of 4 prime-boost combinations of HIV vaccine candidates (MVA HIV-B/LIPO-5; LIPO-5/MVA HIV-B; GTU-MultiHIV B/LIPO-5; GTU-MultiHIV B/MVA HIV-B) in healthy volunteers at low risk of HIV infection (ANRS VRI01)

Proposed period of release:
01/12/2013 to 31/01/2015

Name of the Institute(s) or Company(ies)
Institut national de la santé et de la recherche médicale, Agence nationale de recherches sur le sida et
les hépatites virales (Inserm-ANRS)
101 rue de Tolbiac
75013 PARIS;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
Other: Naked plasmid DNA

Identity of the GMO:
GTU-MultiHIV B Naked Plasmid DNA Vaccine

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
Escherichia coliEscherichiacoliN/AAG-1. Brasilense Sp245N/A

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known